Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar
Date
2022Author
Abu-Raddad, Laith J.Chemaitelly, Hiam
Ayoub, Houssein H.
Yassine, Hadi M.
Abdul Rahim, Hanan F.
Nasrallah, Gheyath K.
Benslimane, Fatiha M.
Al Khatib, Hebah A.
Al Khal, Abdullatif
Coyle, Peter
Al Kuwari, Einas
Butt, Adeel A.
Kaleeckal, Anvar H.
Shaik, Riyazuddin M.
Al Kanaani, Zaina
Latif, Ali Nizar
Jeremijenko, Andrew
Tang, Patrick
Hasan, Mohammad R.
Al Kuwari, Mohamed Ghaith
Bertollini, Roberto
Al Romaihi, Hamad Eid
Al Thani, Mohamed H.
The National Study Group for COVID-19 Vaccination
...show more authors ...show less authors
Metadata
Show full item recordAbstract
In early 2021, Qatar launched a mass immunization campaign with the mRNA-1273 (Moderna)1 vaccine against coronavirus disease 2019 (Covid-19).2 We assessed the persistence of real-world vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and against Covid-19-related hospitalization and death.We used a test-negative, case-control study design to estimate vaccine effectiveness, applying the same methods used recently to assess waning effectiveness of the BNT162b2 (Pfizer-BioNTech) vaccine in the same population.3 Case participants (persons with a positive polymerase-chain-reaction [PCR] test for SARS-CoV-2) and controls (PCR-negative persons) were matched one to one according to sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test. Effectiveness was estimated against documented infection (a PCR-positive swab, regardless of the presence of symptoms) and against any severe Covid-19 cases (acute-care hospitalizations), critical Covid-19 cases (intensive care unit hospitalizations), or fatal Covid-19 cases (Covid-19-related deaths).
Collections
- Biomedical Sciences [707 items ]
- COVID-19 Research [809 items ]